Médecine

Paramédical

Autres domaines


S'abonner

C014 Endothelial dysfunction in isolated perfused kidneys of L-NAME-treated spontaneous hypertensive rats - 17/04/09

Doi : 10.1016/S1875-2136(09)72201-6 
S. Simonet, M. Bousquenaud, M.-J. Isabelle, C. Vayssettes-Courchay, M. Feletou, T.-J. Verbeuren
Institut De Recherches Servier, Suresnes, France 

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

In hypertensive humans, the development of end-stage renal disease is often associated with an endothelial dysfunction attributed to a decrease in the bioavailability of nitric oxide (NO). An early endothelial dysfunction is also reported in most animal models of hypertension and profound alterations in renal function are observed in aged hypertensive animals. As kidneys play an important role in blood pressure regulation, the purpose of the present study was to determine whether a chronic treatment with a NO synthase inhibitor, L-NAME (Nω- nitro-L-arginine methyl ester) accelerates the renal dysfunction in younger adult spontaneously hypertensive rats (SHR). Indeed, in this model, the alterations in cardiac function mimic those observed in aging SHR. Male SHR were subjected to chronic L-NAME-treatment (6 mg/ kg/day) for two weeks. At 19 weeks, the kidneys were isolated, perfused with oxygenated physiological salt solution and changes in renal perfusion pressure continuously recorded. During a sustained constriction caused by methoxamine, bolus injections of acetylcholine and of the NO donor sodium nitroprusside caused dose-dependent dilatations in both groups of SHR. The responses to acetylcholine were not affected by the L-NAME treatment while those to sodium nitroprusside were significantly augmented. In the two groups, indomethacin, a cyclooxygenase inhibitor, did not affect the vasodilatation caused by acetylcholine. However, an acute treatment with another NO synthase inhibitor, L-nitroarginine, produced a major inhibition of the acetylcholine response in the SHR while it did not affect it in the kidney of SHR chronically treated with L-NAME. In the presence of indomethacin plus L-nitro-arginine, TRAM-34, an inhibitor of Ca2+-activated K+ channels of intermediate conductance, IK(Ca), blocked the responses to acetylcholine in both groups of SHR. These data show that in SHR, the acetylcholine-induced vasodilatation involves both NO release and an endothelium-derived hyperpolarizing factor (EDHF)-mediated component while in the L-NAME-treated SHR, the NO-component is abolished and the EDHF-mediated component becomes the major contributor to this vasodilatation. In the kidney of L-NAME-treated SHR, EDHF-mediated responses are a compensatory mechanism that sustain endothelium-dependent dilatations when NO activity is impaired. The responses involve IK(Ca), activation and must be further characterized.

Le texte complet de cet article est disponible en PDF.

Plan

Plan indisponible

© 2009  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 102 - N° S1

P. S31-S32 - mars 2009 Retour au numéro
Article précédent Article précédent
  • C013 Cocaine-induced LV diastolic impairment is associated with cardiac mitochondrial dysfunction and ROS production: role of nadph and xanthine oxidase
  • A. Vergeade, P. Mulder, C. Dehaudt, D. Fortin, R. Ventura-Clapier, C. Thuillez, C. Monteil
| Article suivant Article suivant
  • C015 Identification of new biomarkers of vascular smooth muscle cells ageing from transcriptomic and mirna studies
  • A. Marchand, F. Atassi, P. Leprince, C. Lefeuvre, S. Nadaud, A.-M. Lompre

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.